[1] |
Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosino-philic syndrome[J]. N Engl J Med, 2003, 348:1201-1214.
|
[2] |
Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy[J]. Blood, 2003, 102:3093-3096.
|
[3] |
Tzankov A, Reichard KK, Hasserjian RP, et al. Updates on eosinophilic disorders[J]. Virchows Arch, 2023, 482:85-97.
|
[4] |
Cools J, Quentmeier H, Huntly BJ, et al. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia[J]. Blood, 2004, 103:2802-2805.
|
[5] |
Metzgeroth G, Walz C, Score J, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma[J]. Leukemia, 2007, 21:1183-1188.
|
[6] |
Ali S, Al-Qattan Y, Awny W, et al. FIP1L1-PDGFRA fusion gene in T-lymphoblastic lymphoma: a case report[J]. Cancer Rep (Hoboken), 2023, 6:e1769-1774.
|
[7] |
Kim TH, Gu HJ, Lee WI, et al. Chronic eosinophilic leukemia with FIP1L1-PDGFRA rearrangement[J]. Blood Res, 2016, 51:204-206.
|
[8] |
Shomali W, Gotlib J. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management[J]. Am J Hematol, 2022, 97:129-148.
|
[9] |
Form Lierman E, Michaux L, Beullens E, et al. FIP1L1-PDGFRα D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRα T674I eosinophilic leukemia with single agent sorafenib.[J]. Leukemia, 2009, 23:845-851.
|
[10] |
Kang YK, George S, Jones RL, et al. Avapritinib versus Regorafenib in locally advanced unresectable or metastatic GI stromal tumor: a randomized, open-label phase Ⅲ study[J]. J Clin Oncol, 2021, 39:3128-3139.
|
[11] |
Jin Y, Ding K, Li H, et al. Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin[J]. Mol Cancer, 2014, 13:1-15.
|
[12] |
Zhou Y, Xiang S, Yang F, et al. Targeting gatekeeper mutations for kinase drug discovery[J]. J Med Chem, 2022, 65:15540-15558.
|
[13] |
Metzgeroth G, Erben P, Martin H, et al. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation[J]. Leukemia, 2012, 26:162-164.
|
[14] |
Klug LR, Kent JD, Heinrich MC. Structural and clinical consequences of activation loop mutations in class Ⅲ receptor tyrosine kinases[J]. Pharmacol Ther, 2018, 191:123-134.
|